James M Angelastro, PhD; BS

Associate Professor

UC Davis, School of Veterinary Medicine

Emailjmangelastro@ucdavis.edu

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where James M Angelastro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

3 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

2 Finished

Using Cell-Penetrant Peptides to Target ATF5 in Mouse Glioma Models
Angelastro, J. M.
National Institutes of Health
2/15/14 → 1/31/19
Project: Research project
Elimination of Carcinogen-Induced Tumor Stem Cells by ATF5 Loss of Function.
Angelastro, J. M.
National Institutes of Health
7/1/08 → 6/30/11
Project: Research project

1772 Citations
21 h-Index
41 Article
2 Chapter
1 Short survey
1 Review article

Cetylpyridinium chloride is a potent AMP-activated kinase (AMPK) inducer and has therapeutic potential in cancer
Allen, S. A., Datta, S., Sandoval, J., Tomilov, A., Sears, T., Woolard, K., Angelastro, J. M. & Cortopassi, G. A., Jan 2020, In : Mitochondrion. 50, p. 19-24 6 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Dominant-negative ATF5 compromises cancer cell survival by targeting CEBPB and CEBPD
Sun, X., Jefferson, P., Zhou, Q., Angelastro, J. M. & Greene, L. A., Feb 1 2020, In : Molecular Cancer Research. 18, 2, p. 216-228 13 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
PRMT1 promotes neuroblastoma cell survival through ATF5
Hua, Z. Y., Hansen, J. N., He, M., Dai, S. K., Choi, Y., Fulton, M. D., Lloyd, S. M., Szemes, M., Sen, J., Ding, H. F., Angelastro, J. M., Fei, X., Li, H. P., Wu, C. R., Yang, S. Y., Malik, K., Bao, X., George Zheng, Y., Liu, C. M., Schor, N. F. & 2 others, Li, Z. J. & Li, X. G., May 1 2020, In : Oncogenesis. 9, 5, 50.
Research output: Contribution to journal › Article › peer-review

Open Access
Dominant-negative ATF5 rapidly depletes survivin in tumor cells
Sun, X., Angelastro, J. M., Merino, D., Zhou, Q., Siegelin, M. D. & Greene, L. A., Oct 1 2019, In : Cell Death and Disease. 10, 10, 709.
Research output: Contribution to journal › Article › peer-review

Open Access
Expression and targeting of transcription factor ATF5 in dog gliomas
York, D., Sproul, C. D., Chikere, N., Dickinson, P. J. & Angelastro, J. M., 2017, (Accepted/In press) In : Veterinary and Comparative Oncology.
Research output: Contribution to journal › Article › peer-review
3 Scopus citations

Using Cell-Penetrant Peptides to Target ATF5 in Mouse Glioma Models

Elimination of Carcinogen-Induced Tumor Stem Cells by ATF5 Loss of Function.

Cetylpyridinium chloride is a potent AMP-activated kinase (AMPK) inducer and has therapeutic potential in cancer

Dominant-negative ATF5 compromises cancer cell survival by targeting CEBPB and CEBPD

PRMT1 promotes neuroblastoma cell survival through ATF5

Dominant-negative ATF5 rapidly depletes survivin in tumor cells

Expression and targeting of transcription factor ATF5 in dog gliomas